-
Treatment for FSHD named orphan drug, put on FDA fast track
The U.S. Food and Drug Administration (FDA) has granted both fast track and orphan drug designations to Scholar Rock‘s apitegromab as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD), a disease type that characteristically affects muscles of the face and upper body. The experimental muscle-targeted therapy, which aims to improve motor function in FSHD, is…
-
Guest Voice: 10 years after my son’s desperate plea to the FDA
On April 25, 2016, my son Billy stood at a podium in a hotel ballroom outside Washington, D.C., and told a room full of advisers from the U.S. Food and Drug Administration (FDA) something no 15-year-old should have to say out loud. “FDA, please don’t let me die early,” he said. This September marks 10…








